An Open Label, First in Human (FIH), Phase 1a/1b Trial of LVGN7409 (CD40 Agonist Antibody) as a Single Agent, in Combination With LVGN3616 (Anti-PD-1 Antibody), and in Combination With LVGN3616 and LVGN6051 (CD137 Agonist Antibody) in Patients With Locally Advanced, Relapsed, Refractory, or Metastatic Malignancy
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 66
- 试验地点
- 2
- 主要终点
- Treatment-emergent adverse events (TEAEs)
研究概览
简要总结
LVGN7409 is a humanized monoclonal antibody that specifically binds to CD40, and acts as an agonist against CD40.
This first in human study of LVGN7409 is designed to establish the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) as well as the recommended Phase 2 dose(s) (RP2D) of LVGN7409, both as a single agent (monotherapy) and in combination with a fixed dose of anti-PD-1 antibody and/or CD137 agonist in the treatment of advanced or metastatic malignancy.
详细描述
This is an open-label, non-randomized, two-stage, FIH Phase 1 study, utilizing an accelerated dose escalation followed by a traditional 3 + 3 dose escalation algorithm to identify the MTD and/or RDE and RP2D of LVGN7409 as a single agent (monotherapy) and in combination with anti-PD-1 antibody and/or CD137 agonist. The first stage of the study is the dose escalation phase (i.e., Phase 1a). The second stage of the study is the dose expansion phase (i.e., Phase 1b). During the study, dose interruption(s) and/or delay(s) may be implemented based on toxicity. Dose modifications are not permitted. Intra-patient dose escalations will be allowed for the early dose cohorts (single-patient dose groups) in Phase 1a Part 1. Patients will be considered evaluable for safety and tolerability if they receive at least one dose of LVGN7409 or anti-PD-1 antibody and/or CD137 agonist at the specified cohort dose. Patients in all parts of the trial will remain on therapy until confirmed disease progression or for 2 years, whichever occurs first. However, patients who are clinically unstable will discontinue following the initial assessment of disease progression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or females aged ≥ 18 years.
- •Ability to understand and willingness to sign a written informed consent document.
- •Patients must have a histologically or cytologically confirmed metastatic or unresectable malignancy.
- •Estimated life expectancy, in the judgment of the Investigator, of at least 90 days.
- •Adequate bone marrow, liver, and renal functions
- •Men and women of childbearing potential must agree to take highly effective contraceptive methods.
- •Patients should recover from all reversible AEs of previous anticancer therapies to baseline.
- •Patients infected with the HIV virus will be eligible if the disease is under control of effective therapy.
排除标准
- •Prior therapy with anti-CD40 therapy.
- •Receipt of systemic anticancer therapy or radiotherapy within certain period of time.
- •Prior exposure to immune-therapeutics experienced Grade ≥ 3 drug-related toxicity, or a toxicity requiring discontinuation.
- •Received a live-virus vaccine within 30 days of the first dose of study drug.
- •Grade ≥ 3 allergic reaction to treatment with a monoclonal antibody.
- •History of Grade ≥ 3 immune-related AEs (irAEs).
- •Prolonged QT syndrome, or clinically significant cardiac condition.
- •Receiving an immunologically based treatment for any reason.
- •History or current active or chronic autoimmune disease.
- •Uncontrolled pleural effusion, pericardial effusion, or recurrent ascites drainage.
- •Female patients who are pregnant or breastfeeding.
- •History of hemorrhagic or ischemic stroke within the last 6 months.
- •Previously received an allogeneic tissue/organ transplant, stem cell or bone marrow transplant or solid organ transplant.
研究组 & 干预措施
Monotherapy dose escalation
The monotherapy dose escalation phase includes 8 dose levels of LVGN7409. Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
干预措施: LVGN7409 (Biological)
结局指标
主要结局
Treatment-emergent adverse events (TEAEs)
时间窗: up to 24 months
determination of DLTs and serious AEs (SAEs) of LVGN7409 as monotherapy. Adverse events will be assessed, and severity will be assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
RP2D of LVGN7409 as monotherapy
时间窗: up to 24 months
determination of MTD, RDE and/or RP2D of LVGN7409 as monotherapy
次要结局
未报告次要终点